AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7232461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30676323 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Kinesio Taping (KT) application
Number of subjects: 40
Study 30676323 — intervention group
Group type: COMPARATOR
Intervention: Sham Kinesio Taping (KT) application
Number of subjects: 40
Study 27563177 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne (Group WO)
Number of subjects: 152
Study 27563177 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal (Group PU)
Number of subjects: 152
Study 27563177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo (Group Mt)
Number of subjects: 152
Study 27563177 — intervention group
Group type: COMPARATOR
Intervention: Control (nonvital teeth)
Number of subjects: 152
Study 24979315 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Stepping Stones Triple P (intervention group)
Number of subjects: 64
Study 24979315 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 64
Study 22736123 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized fluid therapy
Number of subjects: 60
Study 22736123 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid therapy
Number of subjects: 60
Study 20138272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor-phase nitrogen storage
Number of subjects: 90
Study 20138272 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen storage
Number of subjects: 90
Study 18525035 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nevirapine
Number of subjects: 3016
Study 18525035 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dual prophylaxis (nevirapine plus zidovudine)
Number of subjects: 3016
Study 18525035 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (single‐dose nevirapine plus 1 week of zidovudine)
Number of subjects: 3016
Study 15715193 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600mg/d) for 10 weeks
Number of subjects: 0
Study 15715193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1000 microg/d) for 10 weeks
Number of subjects: 0
Study 15715193 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600mg/d) and Fluticasone propionate (1000 microg/d) for 10 weeks
Number of subjects: 0
Study 12079630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.45 microm diode laser treatment with an average power of 12 W, heating times from 150 ms to 500 ms, applied over two to six treatment cycles.
Number of subjects: 10
Study 10623054 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 98000
Study 10623054 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 98000
Study 7564350 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg quinapril plus 12.5 mg hydrochlorothiazide (HCTZ)
Number of subjects: 291
Study 7564350 — intervention group
Group type: COMPARATOR
Intervention: 20 mg quinapril monotherapy
Number of subjects: 291
Study 7564350 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 291
Study 7564350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (quinapril + HCTZ)
Number of subjects: 291
Study 2209135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus triamterene 200 mg
Number of subjects: 10
Study 2209135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus spironolactone 100 mg
Number of subjects: 10
Study 2209135 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide plus triamterene 50 mg
Number of subjects: 10
Study 2209135 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 10
Study 2209135 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose triamterene
Number of subjects: 10
Study 2209135 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study 7188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol (400-800 mg/day)
Number of subjects: 24
Study 7188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol (mean: 447 mg once daily)
Number of subjects: 24
Study 7188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol (mean: 700 mg once daily)
Number of subjects: 24
Study 7188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol
Number of subjects: 24
Study 30618355 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated words in discourse
Number of subjects: 0
Study 30618355 — intervention group
Group type: EXPERIMENTAL
Intervention: Word identification task
Number of subjects: 0
Study 31117809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) sinus implant (1350 mcg) and MF nasal spray (MFNS)
Number of subjects: 400
Study 31117809 — intervention group
Group type: COMPARATOR
Intervention: MF nasal spray (MFNS) alone
Number of subjects: 400
Study 29072002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of 'Yaotong'-point and local Ashi-points for 20 min, combined with lumbar movement, 3 times a week for 1 week
Number of subjects: 46
Study 29072002 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with oral loxoprofen sodium tablets (60 mg, twice a day, for one week)
Number of subjects: 46
Study 29072002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups showed significant decrease in ROM and VAS scores post-treatment (P<0.01)
Number of subjects: 46
Study 24785978 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (medium potency)
Number of subjects: 656
Study 23941282 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified balloon dilatation treatment and regular dysphagia therapy
Number of subjects: 30
Study 23941282 — intervention group
Group type: COMPARATOR
Intervention: Regular dysphagia therapy only
Number of subjects: 30
Study 21217456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 351
Study 21217456 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 351
Study 19835591 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) applied with a sponge (40 units each nostril)
Number of subjects: 20
Study 19835591 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 20
Study 19835591 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medication (BTA or saline) for non-responders in subgroups C and D
Number of subjects: 20
Study 16639069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteral nutrition supplement plus supplemental parenteral nutrition (PN+)
Number of subjects: 152
Study 14964681 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo (OS)
Number of subjects: 25
Study 14964681 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (SB1)
Number of subjects: 25
Study 14964681 — intervention group
Group type: EXPERIMENTAL
Intervention: SB1+Revolution (R)
Number of subjects: 25
Study 14964681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop (PLP)
Number of subjects: 25
Study 14964681 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (SB1) with flowable composite layer
Number of subjects: 25
Study 10960403 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 degrees C treated tube group
Number of subjects: 150
Study 10960403 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 degrees C treated tube group
Number of subjects: 150
Study 10960403 — intervention group
Group type: COMPARATOR
Intervention: untreated tube group
Number of subjects: 150
Study 9026581 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid in aqueous humor of patients with cataract
Number of subjects: 32
Study 9026581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 32
Study 9026581 — intervention group
Group type: COMPARATOR
Intervention: Comparison between cataract patients and control group
Number of subjects: 32
Study 1538348 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise intervention
Number of subjects: 83
Study 1538348 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 83
Study 6239300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Haloperidol (0.014 mg/kg IM)
Number of subjects: 12
Study 6239300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Propranolol (0.1 mg/kg IV)
Number of subjects: 12
Study 6239300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Thymoxamine (0.1 mg/kg IV)
Number of subjects: 12
Study 6239300 — intervention group
Group type: COMPARATOR
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Placebo
Number of subjects: 12
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to second- and third-generation cephalosporins
Number of subjects: 0
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to fluoroquinolones
Number of subjects: 0
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hospitalisation
Number of subjects: 0
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Being elderly
Number of subjects: 0
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 0
Study 31065996 — intervention group
Group type: EXPERIMENTAL
Intervention: Having genitourinary disease
Number of subjects: 0
Study 27206564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS)
Number of subjects: 1882
Study 27206564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia morphine (IV PCA morphine)
Number of subjects: 1882
Study 26348166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 746
Study 26348166 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 746
Study 23026438 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 285
Study 23026438 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 250 μg
Number of subjects: 285
Study 23026438 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 500 μg
Number of subjects: 285
Study 23026438 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Number of subjects: 285
Study 23026438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 20740685 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly
Number of subjects: 189
Study 20740685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 19830352 — intervention group
Group type: EXPERIMENTAL
Intervention: Single phototherapy
Number of subjects: 77
Study 19830352 — intervention group
Group type: EXPERIMENTAL
Intervention: Double phototherapy
Number of subjects: 77
Study 16887429 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate treatment (2 mg/kg administered intravenously for 2 consecutive days, every 3 months)
Number of subjects: 10
Study 14962524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (16 mmol over 15 min and then 65 mmol over 24 h)
Number of subjects: 2589
Study 14962524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2589
Study 14962524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2589
Study 11298538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% SDZ ASM 981 cream
Number of subjects: 260
Study 11298538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% SDZ ASM 981 cream
Number of subjects: 260
Study 11298538 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% SDZ ASM 981 cream
Number of subjects: 260
Study 11298538 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone-17-valerate cream (BMV)
Number of subjects: 260
Study 11298538 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 260
Study 9613279 — intervention group
Group type: EXPERIMENTAL
Intervention: Whoosh test (injection of air into the caudal epidural space)
Number of subjects: 131
Study 9613279 — intervention group
Group type: COMPARATOR
Intervention: Clinical impression alone
Number of subjects: 131
Study 7924125 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day cetirizine
Number of subjects: 25
Study 7924125 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day cetirizine
Number of subjects: 25
Study 7924125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2539937 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 3100 kJ cold meal
Number of subjects: 12
Study 1100055 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalase (Optidase) injections
Number of subjects: 648
Study 1100055 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without catalase
Number of subjects: 648
Study 1100055 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalase (Optidase) injections in extended study
Number of subjects: 648
Study 31782562 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (SY)
Number of subjects: 360
Study 31782562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (SS)
Number of subjects: 360
Study 31782562 — intervention group
Group type: COMPARATOR
Intervention: Se-Unsupplemented control diet
Number of subjects: 360
Study 31099442 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed free-running T1 mapping method
Number of subjects: 9
Study 31099442 — intervention group
Group type: COMPARATOR
Intervention: Saturation recovery single-shot acquisition (SASHA) sequence
Number of subjects: 9
Study 31099442 — intervention group
Group type: COMPARATOR
Intervention: Modified Look-Locker inversion recovery (MOLLI) sequence
Number of subjects: 9
Study 31099442 — intervention group
Group type: COMPARATOR
Intervention: MOLLI sequence
Number of subjects: 9
Study 31099442 — intervention group
Group type: COMPARATOR
Intervention: SASHA sequence
Number of subjects: 9
Study 28619771 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed CPR evaluation
Number of subjects: 0
Study 28619771 — intervention group
Group type: COMPARATOR
Intervention: Concealed CPR evaluation
Number of subjects: 0
Study 25814638 — intervention group
Group type: COMPARATOR
Intervention: iDISK technique
Number of subjects: 36
Study 23435795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention of 15 dietitian visits providing lifestyle advice
Number of subjects: 171
Study 23435795 — intervention group
Group type: COMPARATOR
Intervention: Light (control) intervention of four visits
Number of subjects: 171
Study 23435795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 171
Study 23435795 — intervention group
Group type: COMPARATOR
Intervention: Light (control) intervention
Number of subjects: 171
Study 21463967 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 29
Study 21463967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18262125 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Planned Intensity Modulated Radiotherapy (FPIMRT)
Number of subjects: 43
Study 18262125 — intervention group
Group type: COMPARATOR
Intervention: Conventional Wedge Techniques (CW)
Number of subjects: 43
Study 16836774 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-friendly constraint-induced movement therapy (CI therapy); 6 hours per day for 10 out of 12 consecutive days
Number of subjects: 22
Study 16836774 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-friendly constraint-induced movement therapy (CI therapy)
Number of subjects: 22
Study 16836774 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 22
Study 12015761 — intervention group
Group type: EXPERIMENTAL
Intervention: THP (30 mg/30 mL of normal saline) administered into the bladder within 6 hours after TUR‐Bt
Number of subjects: 170
Study 12015761 — intervention group
Group type: COMPARATOR
Intervention: TUR‐Bt alone
Number of subjects: 170
Study 10523398 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/d)
Number of subjects: 24
Study 10523398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8750123 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood retrieved using the Stryker Consta Vac system
Number of subjects: 10
Study 8750123 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative plasma concentrations of IL-6
Number of subjects: 10
Study 8750123 — intervention group
Group type: COMPARATOR
Intervention: Initial portion of drainage blood from the surgical area
Number of subjects: 10
Study 2033528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) rinse, 15 ml b.i.d. for 7 weeks (2 weeks before crown preparation, 3 weeks during provisional crown placement, 2 weeks after definitive crown cementation)
Number of subjects: 30
Study 2033528 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal oral hygiene without CHX)
Number of subjects: 30
Study 7319758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure meglumines and contrast media with low osmolality
Number of subjects: 72
Study 7319758 — intervention group
Group type: COMPARATOR
Intervention: Variation of the anionic component
Number of subjects: 72
Study 6145480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 6145480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31410618 — intervention group
Group type: EXPERIMENTAL
Intervention: VITAL Start (VS)
Number of subjects: 306
Study 31410618 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 306
Study 29233673 — intervention group
Group type: EXPERIMENTAL
Intervention: DFC traction-assisted ESD (DFC-ESD)
Number of subjects: 640
Study 29233673 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 640
Study 29233673 — intervention group
Group type: EXPERIMENTAL
Intervention: DFC traction-assisted ESD (DFC-ESD) for lesions in the greater curvature of the upper or middle stomach
Number of subjects: 640
Study 29233673 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD for lesions in the greater curvature of the upper or middle stomach
Number of subjects: 640
Study 26654154 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 600 mg, three times a day for 24 weeks
Number of subjects: 94
Study 26654154 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg, three times a day for 24 weeks
Number of subjects: 94
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR stages >90 ml min‐1 1.73 m‐2
Number of subjects: 2323
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR stages <60 ml min‐1 1.73 m‐2
Number of subjects: 2323
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR stages <45 ml min‐1 1.73 m‐2
Number of subjects: 2323
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR impairment
Number of subjects: 2323
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR stages 3b and 4
Number of subjects: 2323
Study 24928634 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR correlation
Number of subjects: 2323
Study 21705148 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to relaxing music
Number of subjects: 154
Study 21705148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting and reading magazines
Number of subjects: 154
Study 21705148 — intervention group
Group type: COMPARATOR
Intervention: Sitting in the waiting-room
Number of subjects: 154
Study 20486374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation‐traction (Group A)
Number of subjects: 300
Study 20486374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation‐turn manual reduction (Group B)
Number of subjects: 300
Study 20486374 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction (Group C)
Number of subjects: 300
Study 17612846 — intervention group
Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 2541
Study 17612846 — intervention group
Group type: EXPERIMENTAL
Intervention: No insurance
Number of subjects: 2541
Study 17612846 — intervention group
Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 2541
Study 16247062 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley procedure with self-treatment
Number of subjects: 80
Study 16247062 — intervention group
Group type: COMPARATOR
Intervention: Epley procedure alone
Number of subjects: 80
Study 16247062 — intervention group
Group type: EXPERIMENTAL
Intervention: self-treatment
Number of subjects: 80
Study 12417776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (UT)
Number of subjects: 30
Study 12417776 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy with cold steel instruments (BT)
Number of subjects: 30
Study 10939030 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg/m2-cisplatin (group A)
Number of subjects: 159
Study 10939030 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 180 mg/m2-cisplatin (group B)
Number of subjects: 159
Study 8748403 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lithium carbonate treatment (700 mg)
Number of subjects: 40
Study 8748403 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day lithium carbonate treatment (1200 mg)
Number of subjects: 40
Study 8748403 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA at 75 mg/m2
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA at 65 mg/m2
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA (general)
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA (in previously treated ovarian cancer patients)
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA pharmacokinetics
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: TEPA pharmacokinetics
Number of subjects: 27
Study 1710167 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA and TEPA
Number of subjects: 27